Morgan Stanley Esperion Therapeutics, Inc. Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Morgan Stanley holds 2,646,199 shares of ESPR stock, worth $6.38 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,646,199

Previous 3,328,854 20.51%

Holding current value

$6.38 Million

Previous $7.39 Million 40.92%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$1.61 - $2.73 $1.1 Million - $1.86 Million	-682,655 Reduced 20.51%	2,646,199 $4.37 Million
Q2 2024 Oct 17, 2024	BUY	$1.84 - $3.24 $3.1 Million - $5.46 Million	1,686,494 Added 102.69%	3,328,854 $7.39 Million
Q2 2024 Aug 14, 2024	BUY	$1.84 - $3.24 $3.1 Million - $5.46 Million	1,686,494 Added 102.69%	3,328,854 $7.39 Million
Q1 2024 Oct 17, 2024	SELL	$2.02 - $3.02 $3.41 Million - $5.09 Million	-1,686,494 Reduced 50.66%	1,642,360 $4.4 Million
Q1 2024 Aug 16, 2024	BUY	$2.02 - $3.02 $1.09 Million - $1.62 Million	537,360 Added 48.63%	1,642,360 $4.4 Million
Q1 2024 May 15, 2024	BUY	$2.02 - $3.02 $1.09 Million - $1.62 Million	537,360 Added 48.63%	1,642,360 $4.4 Million
Q4 2023 Aug 16, 2024	SELL	$0.73 - $3.08 $1.62 Million - $6.85 Million	-2,223,854 Reduced 66.81%	1,105,000 $3.3 Million
Q4 2023 Feb 13, 2024	SELL	$0.73 - $3.08 $729,109 - $3.08 Million	-998,780 Reduced 47.48%	1,105,000 $3.3 Million
Q3 2023 Nov 15, 2023	BUY	$0.96 - $1.79 $1.09 Million - $2.04 Million	1,138,359 Added 117.91%	2,103,780 $2.06 Million
Q2 2023 Aug 14, 2023	SELL	$1.2 - $1.76 $544,321 - $798,337	-453,601 Reduced 31.97%	965,421 $1.34 Million
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $536,113 - $2.68 Million	-367,201 Reduced 20.56%	1,419,022 $2.26 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $3.95 Million - $6.6 Million	776,442 Added 76.89%	1,786,223 $11.1 Million
Q3 2022 Nov 14, 2022	BUY	$5.45 - $8.13 $1.17 Million - $1.75 Million	215,070 Added 27.06%	1,009,781 $6.77 Million
Q2 2022 Oct 27, 2022	BUY	$4.77 - $6.67 $2.02 Million - $2.83 Million	423,720 Added 114.21%	794,711 $5.05 Million
Q2 2022 Aug 15, 2022	BUY	$4.77 - $6.67 $2.02 Million - $2.83 Million	423,720 Added 114.21%	794,711 $5.05 Million
Q1 2022 Oct 27, 2022	SELL	$3.34 - $5.56 $1.42 Million - $2.36 Million	-423,720 Reduced 53.32%	370,991 $1.72 Million
Q1 2022 May 13, 2022	SELL	$3.34 - $5.56 $247,898 - $412,668	-74,221 Reduced 16.67%	370,991 $1.72 Million
Q4 2021 Feb 14, 2022	SELL	$4.81 - $11.92 $31,803 - $78,815	-6,612 Reduced 1.46%	445,212 $2.23 Million
Q3 2021 Nov 15, 2021	BUY	$11.34 - $21.37 $5.12 Million - $9.66 Million	451,824 New	451,824 $5.44 Million

Others Institutions Holding ESPR

# of Institutions

208

Shares Held

128M

Call Options Held

1.67M

Put Options Held

930K

View Full List

About Esperion Therapeutics, Inc.

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $160M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

More about ESPR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account